$PLX Attempt to save Fabrazyme (Jan 2021 Letter to Annals of Allergy, Asthma & Immunology): "Successful desensitization of a patient with Fabry disease with agalsidase beta (Fabrazyme) anaphylaxis after omalizumab pretreatment" sciencedirect.com/science/a... 5 monthly doses of omalizumab (300mg subcutaneous injections) overcame drug (fabrazyme) allergies. Pretreatment of Omalizumab is continued to be needed to suppress anaphylactic reactions. The key is thought to be the ability of the drug to remove the memory B cells. I don't see this being enough to save Fabrazyme.
  • 1
1 Like